U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C28H30FN3OS
Molecular Weight 475.621
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MONATEPIL

SMILES

FC1=CC=C(C=C1)N2CCN(CCCC(=O)NC3C4=C(CSC5=C3C=CC=C5)C=CC=C4)CC2

InChI

InChIKey=WFNRNNUZFPVBSM-UHFFFAOYSA-N
InChI=1S/C28H30FN3OS/c29-22-11-13-23(14-12-22)32-18-16-31(17-19-32)15-5-10-27(33)30-28-24-7-2-1-6-21(24)20-34-26-9-4-3-8-25(26)28/h1-4,6-9,11-14,28H,5,10,15-20H2,(H,30,33)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/7496051

Monatepil is a calcium antagonist that, as do existing calcium antagonists, inhibits the influx of extracellular Ca 2 + through voltage-dependent Ca 2 + channels. It is a new type of antihypertensive agent. Its unique chemical structure was specially designed with intrinsic calcium antagonist and a1 -adrenoceptor-blocking moieties, creating a dual mechanism of action. Positive effects on plasma lipid metabolism are derived from the a1 -adrenoceptor-blocking activity and the antiatherosclerotic effect derives from the calcium antagonist properties. The novel structure of monatepil produces a slow onset of action and a long-lasting antihypertensive effect in experimental animals.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Acyl-CoA:cholesterol acyltransferase (Macaca fuscata)
20.8 nM [IC50]
16.0 nM [IC50]
Target ID: Lipid hydroperoxidation of low density lipoprotein
28.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of vasoconstriction by AJ-2615, a novel calcium antagonist with alpha(1)-adrenergic receptor blocking activity in human conduit arteries used as bypass grafts.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Treatment of essential hypertension: The initial dose of monatepil was 30 mg/day in monotherapy and 15 mg/day in combination therapy; the daily dose was titrated to 60 mg/day according to the antihypertensive response.
Route of Administration: Oral
In Vitro Use Guide
Treatment of human skin fibroblasts with 2 x 10(-5) M of monatepil for 6 hours resulted in an increase in LDL receptor mRNA to 163% of the control level
Name Type Language
MONATEPIL
INN   MI  
INN  
Official Name English
1-PIPERAZINEBUTANAMIDE, N-(6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-4-(4-FLUOROPHENYL)
Common Name English
monatepil [INN]
Common Name English
MONATEPIL [MI]
Common Name English
(±)-N-(6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-4-(P-FLUOROPHENYL)-1-PIPERAZINEBUTYRAMIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
Code System Code Type Description
WIKIPEDIA
MONATEPIL
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
CAS
132019-54-6
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
SUPERSEDED
FDA UNII
N4MMI0J7PW
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
MESH
C067818
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
INN
6999
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
MERCK INDEX
m832
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY Merck Index
EVMPD
SUB09047MIG
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
CAS
103377-41-9
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
NCI_THESAURUS
C83970
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID3048811
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
PUBCHEM
60810
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL172853
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY
SMS_ID
100000080359
Created by admin on Fri Dec 15 16:05:22 GMT 2023 , Edited by admin on Fri Dec 15 16:05:22 GMT 2023
PRIMARY